Ketamine Research by Condition
Different conditions have different evidence bases. Here's where each one stands.
This page has been written and edited by the publisher. It has not been reviewed by a licensed clinician.
Browse by condition
Largest evidence base; rapid onset; durable with maintenance.
FDA-approved esketamine indication; foundational evidence.
Generalized and social anxiety; growing evidence base.
Multiple positive trials; integration is critical.
Smaller evidence base; rapid acute effects in some patients.
Used for CRPS, neuropathic pain, and other syndromes.
Treated with caution; mood-stabilizer coordination essential.
Rapid reduction; bridge to ongoing care.
Educational content only. Not medical advice. Discuss any treatment decisions with a qualified clinician.
Publisher and editor of Ketalux, based in Chicago, Illinois. Ira is a ketamine therapy patient, not a clinician. This is editorial review, not medical review: Ira is not a licensed clinician and does not provide diagnosis or medical care. Ketalux does not accept compensation from providers in exchange for favorable editorial coverage, evidence ratings, recommendations, patient referrals, or organic provider ranking. Read the full publisher disclosure →
Educational use only. The content on this page is provided for general educational purposes and does not constitute medical advice, diagnosis, or treatment. Ketamine and related therapies carry risks and are appropriate only under qualified medical supervision. Always consult a licensed healthcare professional about your individual situation. Information may change as research evolves.